India's largest biopharmaceuticals company, Biocon, declared its maiden quarterly and annual results. Since the comparative figures for 4QFY04 are not available, we will focus on the yearly comparison. Total sales of the company has increased by 94% to Rs 5.5 bn while the net profit has risen by 219% to Rs 1.4 bn. Operating profit margin stood at 34% compared to 29%, which is due to better economies of scale. The net profit margin stood at 28% due to lower interest outgo and higher operating margins.
Results at a glance...
Operating profit (EBDITA)
Operating profit margin (%)
Profit before tax
Profit after tax/(loss)
Net profit margin (%)
No. of shares (m)
Diluted earnings per share (Rs)*
P/E ratio (x)
The major growth came from exports (up 150% and 63% of sales) on the back of strong performance by statins and immunosuppressants. Statins are the molecules used for the treatment of cardiovascular disease, which is one of the fastest growing therapeutic segment, both nationally and internationally. The company has gained significant market share in the US and European market as the supplier of off patent statins. Statins, in fact, contribute to 56% of the consolidated revenues of Biocon. The following chart shows the contribution of revenue by statins over last 4 years.
Its not only the statins that have shown phenomenal growth but also the other segments like anti-diabetics, neutraceuticals, gynecology and anti-osteoporosis have also shown robust growth. The table below gives a perspective on the company's growth in various segments.
The company's plants are USFDA approved, which gives it a chance to expand its market in simvastatin, which will go off patent in the US market from the year 2006. The total size of simvastatin is estimated to be US$ 6 bn. More importantly, the company has signed an agreement with the Bristol Myers Squibb for the supply of recombinant human insulin, which is likely to be in the markets by the 2QFY05.
On domestic front, Biocon has launched 11 formulations in the cardio-diabetic therapeutic segment under its own brand name. The greater challenge lies in marketing of these products, on which one is likely to have some visibility by the end of 2QFY05.
The company is very well known for its focus on R&D activities. It spends about 5% of its revenue in R&D activities. Earlier, Biocon focussed on process development but now it is also working towards product development. It has filed 88 patent applications in the FY04. The two entities of the company, which are purely dedicated towards research (including custom research and clinical research), have shown a good performance in FY04. These subsidiaries also provide research services to the third party.
The stock is currently trading at a P/E of 38.5x FY04 earnings. Though valuations may seem expensive, considering the overall strengths from a long-term perspective, valuations are not high on a relative basis. The new contracts earned and the launch of new drugs in the Indian markets is likely to fuel growth. Also, the year 2006 will be crucial for the company when simvastatin will go off patent in the US markets.
LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.
Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India. Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: email@example.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407